 |
Generalized Anxiety Disorder With Comorbid Depression CME Author Information and Disclosures Release Date: November 14, 2008; Valid for credit through November 14, 2009 | Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Discuss the impact and presentation of treatment nonresponse in GAD
- Review emerging pharmacologic augmentation treatment strategies for treating GAD
- Explore how best to integrate nonpharmacologic and pharmacologic
augmentation strategies into clinical practice to improve patient outcomes
Authors and Disclosures Mark H. Pollack, MD
Disclosure: Mark H. Pollack, MD, has disclosed that he has served as an advisor or consultant to AstraZeneca, Brain Cells Inc., Bristol-Myers Squibb, Cephalon, Dov Pharmaceuticals, Forest Laboratories,
GlaxoSmithKline, Janssen, Jazz Pharmaceuticals, Eli Lilly, MedAvante, Neurocrine, Neurogen, Novartis, Otsuka Pharmaceuticals, Pfizer, Predix, Roche, Sanofi, Sepracor, Solvay, Tikvah Therapeutics, Transcept Inc, UCB Pharma, and Wyeth. Dr. Pollack has also disclosed that he has received grants for research from AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, NARSAD, NIDA NIMH, Pfizer, Roche Laboratories, Sepracor, UCB
Pharma, and Wyeth, and has served on speaker's bureau for Bristol-Myers Squibb, Forest Laboratories, GlaxoSmithKline, Janssen, Lilly, Pfizer, Solvay, and Wyeth. Dr. Pollack has also disclosed that he has equity at MedAvante, and Mensante Corporation. Jane Lowers
Disclosure: Jane Lowers has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
